{"transactions":[{"id":699709,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-31T20:15:05.000Z","date":"2026-07-29","kind":"sale","planned":false,"acquired":false,"shares":464,"price":2.7,"value":1252.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1380 to EURO 1.00 as of July 29, 2026."}],"balance_after":144531,"source":{"system":"sec-edgar","filing":"0001760395-26-000008","document":"form4-07312026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000176039526000008/form4-07312026_040701.xml","form_type":"4"}},{"id":924487,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-02T21:30:20.000Z","date":"2026-01-29","kind":"sale","planned":false,"acquired":false,"shares":534,"price":4.86,"value":2595.24,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1974 to EURO 1.00 as of January 29, 2026."}],"balance_after":144995,"source":{"system":"sec-edgar","filing":"0001760395-26-000002","document":"form4-02022026_040211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000176039526000002/form4-02022026_040211.xml","form_type":"4"}},{"id":939559,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Second Pre-Funded Warrant","published_at":"2026-01-14T21:33:18.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":25005240,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 12, 2026, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a \"BS Warrant\") of DBV Technologies S.A. (the \"Issuer\"), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a \"Second Pre-Funded Warrant\"), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"(continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"(continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"(continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":25005240,"derivative":{"underlying":"Ordinary Shares","underlying_shares":43759170},"source":{"system":"sec-edgar","filing":"0001193125-26-012991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526012991/ownership.xml","form_type":"4"}},{"id":939558,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Second Pre-Funded Warrant","published_at":"2026-01-14T21:33:18.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":2299656,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 12, 2026, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a \"BS Warrant\") of DBV Technologies S.A. (the \"Issuer\"), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a \"Second Pre-Funded Warrant\"), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"(continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"(continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"(continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":2299656,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4024398},"source":{"system":"sec-edgar","filing":"0001193125-26-012991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526012991/ownership.xml","form_type":"4"}},{"id":939557,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"BS Warrant","published_at":"2026-01-14T21:33:18.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":25005240,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 12, 2026, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a \"BS Warrant\") of DBV Technologies S.A. (the \"Issuer\"), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a \"Second Pre-Funded Warrant\"), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F8","text":"(continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F9","text":"(continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":0,"derivative":{"expiration_date":"2026-01-15","underlying":"Second Pre-Funded Warrant","underlying_shares":25005240},"source":{"system":"sec-edgar","filing":"0001193125-26-012991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526012991/ownership.xml","form_type":"4"}},{"id":939556,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"BS Warrant","published_at":"2026-01-14T21:33:18.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":2299656,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 12, 2026, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a \"BS Warrant\") of DBV Technologies S.A. (the \"Issuer\"), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a \"Second Pre-Funded Warrant\"), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F7","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F8","text":"(continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F9","text":"(continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"expiration_date":"2026-01-15","underlying":"Second Pre-Funded Warrant","underlying_shares":2299656},"source":{"system":"sec-edgar","filing":"0001193125-26-012991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526012991/ownership.xml","form_type":"4"}},{"id":962400,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":71127,"kind":"person","name":"EPIC Bpifrance","position":1,"cik":"0001731121","reported_name":"EPIC Bpifrance","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71128,"kind":"organization","name":"Bpifrance Participations SA","position":2,"cik":"0001581835","reported_name":"Bpifrance Participations SA","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71129,"kind":"organization","name":"Bpifrance SA","position":3,"cik":"0001731118","reported_name":"Bpifrance SA","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":2137,"kind":"person","name":"Bpifrance Investissement S.A.S.","position":4,"cik":"0002065260","reported_name":"Bpifrance Investissement S.A.S.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71130,"kind":"person","name":"CAISSE DES DEPOTS ET CONSIGNATIONS","position":5,"cik":"0001056947","reported_name":"CAISSE DES DEPOTS ET CONSIGNATIONS","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Ordinary Shares","published_at":"2025-12-19T21:04:06.000Z","date":"2025-12-18","kind":"sale","planned":false,"acquired":false,"shares":1292103,"price":4.19,"value":5413911.57,"ownership":{"direct":false,"nature":"By Bpifrance Participations S.A."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1727 to EURO 1.00 as of December 18, 2025 . The shares were sold in multiple transactions at prices ranging from $3.79 to $4.32 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bpifrance Participations S.A. (\"Bpifrance Participations\") directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. (\"Bpifrance\"). Bpifrance is jointly owned by Caisse des Depots et Consignations (\"CDC\") at 49.2% and EPIC Bpifrance (\"EPIC\") at 49.2%. CDC and EPIC jointly control Bpifrance."}],"balance_after":7303369,"source":{"system":"sec-edgar","filing":"0001104659-25-123104","document":"tm2533970-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1056947/000110465925123104/tm2533970-1_4seq1.xml","form_type":"4"}},{"id":962399,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":71127,"kind":"person","name":"EPIC Bpifrance","position":1,"cik":"0001731121","reported_name":"EPIC Bpifrance","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71128,"kind":"organization","name":"Bpifrance Participations SA","position":2,"cik":"0001581835","reported_name":"Bpifrance Participations SA","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71129,"kind":"organization","name":"Bpifrance SA","position":3,"cik":"0001731118","reported_name":"Bpifrance SA","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":2137,"kind":"person","name":"Bpifrance Investissement S.A.S.","position":4,"cik":"0002065260","reported_name":"Bpifrance Investissement S.A.S.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71130,"kind":"person","name":"CAISSE DES DEPOTS ET CONSIGNATIONS","position":5,"cik":"0001056947","reported_name":"CAISSE DES DEPOTS ET CONSIGNATIONS","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Ordinary Shares","published_at":"2025-12-19T21:04:06.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":5.28,"value":211200.0,"ownership":{"direct":false,"nature":"By Bpifrance Participations S.A."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 reflects the conversion of EURO to USD at an exchange rate of $1.1741 to EURO 1.00 as of December 17, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bpifrance Participations S.A. (\"Bpifrance Participations\") directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. (\"Bpifrance\"). Bpifrance is jointly owned by Caisse des Depots et Consignations (\"CDC\") at 49.2% and EPIC Bpifrance (\"EPIC\") at 49.2%. CDC and EPIC jointly control Bpifrance."}],"balance_after":8595472,"source":{"system":"sec-edgar","filing":"0001104659-25-123104","document":"tm2533970-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1056947/000110465925123104/tm2533970-1_4seq1.xml","form_type":"4"}},{"id":962398,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":71127,"kind":"person","name":"EPIC Bpifrance","position":1,"cik":"0001731121","reported_name":"EPIC Bpifrance","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71128,"kind":"organization","name":"Bpifrance Participations SA","position":2,"cik":"0001581835","reported_name":"Bpifrance Participations SA","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71129,"kind":"organization","name":"Bpifrance SA","position":3,"cik":"0001731118","reported_name":"Bpifrance SA","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":2137,"kind":"person","name":"Bpifrance Investissement S.A.S.","position":4,"cik":"0002065260","reported_name":"Bpifrance Investissement S.A.S.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":71130,"kind":"person","name":"CAISSE DES DEPOTS ET CONSIGNATIONS","position":5,"cik":"0001056947","reported_name":"CAISSE DES DEPOTS ET CONSIGNATIONS","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Ordinary Shares","published_at":"2025-12-19T21:04:06.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":2036990,"price":4.84,"value":9859031.6,"ownership":{"direct":false,"nature":"By Bpifrance Participations S.A."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1741 to EURO 1.00 as of December 17, 2025. The shares were sold in multiple transactions at prices ranging from $4.24 to $5.23 per share, inclusive. The reporting person unterakes to provide DBV Technologies S.A., any security holder of DBV Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 4 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bpifrance Participations S.A. (\"Bpifrance Participations\") directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. (\"Bpifrance\"). Bpifrance is jointly owned by Caisse des Depots et Consignations (\"CDC\") at 49.2% and EPIC Bpifrance (\"EPIC\") at 49.2%. CDC and EPIC jointly control Bpifrance."}],"balance_after":8635472,"source":{"system":"sec-edgar","filing":"0001104659-25-123104","document":"tm2533970-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1056947/000110465925123104/tm2533970-1_4seq1.xml","form_type":"4"}},{"id":988360,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-25T21:15:05.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":253000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":253000,"derivative":{"exercise_price":2.9,"expiration_date":"2035-11-21","underlying":"Ordinary Shares","underlying_shares":253000},"source":{"system":"sec-edgar","filing":"0001760395-25-000003","document":"form4-11252025_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000176039525000003/form4-11252025_041101.xml","form_type":"4"}},{"id":988359,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-25T21:15:05.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":145529,"source":{"system":"sec-edgar","filing":"0001760395-25-000003","document":"form4-11252025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000176039525000003/form4-11252025_041101.xml","form_type":"4"}},{"id":988358,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-25T21:15:05.000Z","date":"2025-11-21","kind":"sale","planned":false,"acquired":false,"shares":1624,"price":2.77,"value":4498.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025."}],"balance_after":101529,"source":{"system":"sec-edgar","filing":"0001760395-25-000003","document":"form4-11252025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000176039525000003/form4-11252025_041101.xml","form_type":"4"}},{"id":988357,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-25T21:15:05.000Z","date":"2025-11-20","kind":"sale","planned":false,"acquired":false,"shares":6496,"price":2.88,"value":18708.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15268 to EURO 1.00 as of November 20, 2025."}],"balance_after":103153,"source":{"system":"sec-edgar","filing":"0001760395-25-000003","document":"form4-11252025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000176039525000003/form4-11252025_041101.xml","form_type":"4"}},{"id":989719,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42317,"kind":"person","name":"Tasse Daniel","position":1,"cik":"0001502785","reported_name":"Tasse Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-25T00:05:05.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":964000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":964000,"derivative":{"exercise_price":2.9,"expiration_date":"2035-11-21","underlying":"Ordinary Shares","underlying_shares":964000},"source":{"system":"sec-edgar","filing":"0001502785-25-000004","document":"form4-11242025_071101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1502785/000150278525000004/form4-11242025_071101.xml","form_type":"4"}},{"id":990339,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72649,"kind":"person","name":"Boucinha Virginie","position":1,"cik":"0001999496","reported_name":"Boucinha Virginie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-24T19:05:09.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":192000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":192000,"derivative":{"exercise_price":2.9,"expiration_date":"2035-11-21","underlying":"Ordinary Shares","underlying_shares":192000},"source":{"system":"sec-edgar","filing":"0001999496-25-000003","document":"form4-11242025_071105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999496/000199949625000003/form4-11242025_071105.xml","form_type":"4"}},{"id":990338,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72649,"kind":"person","name":"Boucinha Virginie","position":1,"cik":"0001999496","reported_name":"Boucinha Virginie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-24T19:05:09.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2026, subject to the\nReporting Person continuing to provide service through each such date."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001999496-25-000003","document":"form4-11242025_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999496/000199949625000003/form4-11242025_071105.xml","form_type":"4"}},{"id":990433,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72658,"kind":"person","name":"Trapp Kevin Michael","position":1,"cik":"0002096014","reported_name":"Trapp Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-24T19:05:07.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":316250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":316250,"derivative":{"exercise_price":2.9,"expiration_date":"2035-11-21","underlying":"Ordinary Shares","underlying_shares":316250},"source":{"system":"sec-edgar","filing":"0002096014-25-000004","document":"form4-11242025_071103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2096014/000209601425000004/form4-11242025_071103.xml","form_type":"4"}},{"id":990432,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72658,"kind":"person","name":"Trapp Kevin Michael","position":1,"cik":"0002096014","reported_name":"Trapp Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-24T19:05:07.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2026, subject to the\nReporting Person continuing to provide service through each such date."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0002096014-25-000004","document":"form4-11242025_071103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096014/000209601425000004/form4-11242025_071103.xml","form_type":"4"}},{"id":1078134,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-31T20:15:16.000Z","date":"2025-07-29","kind":"sale","planned":false,"acquired":false,"shares":464,"price":2.22,"value":1030.08,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1549 to EURO 1.00 as of July 29, 2025."}],"balance_after":109649,"source":{"system":"sec-edgar","filing":"0001415889-25-020722","document":"form4-07312025_040708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588925020722/form4-07312025_040708.xml","form_type":"4"}},{"id":1132930,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-05-27T20:10:06.000Z","date":"2025-05-22","kind":"sale","planned":false,"acquired":false,"shares":397,"price":1.84,"value":730.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1303 to EURO 1.00 as of May 22, 2025."}],"balance_after":110113,"source":{"system":"sec-edgar","filing":"0001415889-25-014602","document":"form4-05272025_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588925014602/form4-05272025_040501.xml","form_type":"4"}},{"id":1188331,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"BS Warrant","published_at":"2025-03-31T22:56:23.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":25005240,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"security","element":"securityTitle","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The BS Warrants will be exercisable until the earlier of April 7, 2027, or 30 days following the publication by the Issuer that the VITESSE Phase 3 study has met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The BS Warrants will be exercisable until the earlier of April 7, 2027, or 30 days following the publication by the Issuer that the VITESSE Phase 3 study has met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F11","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 12)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F12","text":"(continued from Note 11) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 13)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F13","text":"(continued from Note 12) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":25005240,"derivative":{"underlying":"Second Pre-Funded Warrant","underlying_shares":25005240},"source":{"system":"sec-edgar","filing":"0000950170-25-047967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025047967/ownership.xml","form_type":"4"}},{"id":1188330,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"BS Warrant","published_at":"2025-03-31T22:56:23.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":2299656,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"security","element":"securityTitle","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The BS Warrants will be exercisable until the earlier of April 7, 2027, or 30 days following the publication by the Issuer that the VITESSE Phase 3 study has met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The BS Warrants will be exercisable until the earlier of April 7, 2027, or 30 days following the publication by the Issuer that the VITESSE Phase 3 study has met its primary endpoint as further described in the Terms and Conditions of the BS Warrants."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F11","text":"Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant.  The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a \"Second Pre-Funded Warrant Share\") of EUR0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 12)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F12","text":"(continued from Note 11) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"Second Pre-Funded Warrant Beneficial Ownership Limitation\"). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 13)"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F13","text":"(continued from Note 12) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":2299656,"derivative":{"underlying":"Second Pre-Funded Warrant","underlying_shares":2299656},"source":{"system":"sec-edgar","filing":"0000950170-25-047967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025047967/ownership.xml","form_type":"4"}},{"id":1188329,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"First Pre-Funded Warrant","published_at":"2025-03-31T22:56:23.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":25005240,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"security","element":"securityTitle","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The First Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"First Pre-Funded Warrant Beneficial Ownership Limitation\"). (continued in Note 4)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(continued from Note 3) A holder, upon notice to the Issuer, may increase or decrease the First Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the First Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the First Pre-Funded Warrants and (b) the First Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the First Pre-Funded Warrants), (continued in Note 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(continued from Note 4) does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder. and (b) the First Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the First Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder. Any increase in the First Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":25005240,"derivative":{"underlying":"Ordinary Shares","underlying_shares":25005240},"source":{"system":"sec-edgar","filing":"0000950170-25-047967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025047967/ownership.xml","form_type":"4"}},{"id":1188328,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"First Pre-Funded Warrant","published_at":"2025-03-31T22:56:23.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":2299656,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"security","element":"securityTitle","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The First Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 9.99% of the Issuer's outstanding Ordinary Shares (the \"First Pre-Funded Warrant Beneficial Ownership Limitation\"). (continued in Note 4)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(continued from Note 3) A holder, upon notice to the Issuer, may increase or decrease the First Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the First Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the First Pre-Funded Warrants and (b) the First Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the First Pre-Funded Warrants), (continued in Note 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(continued from Note 4) does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder. and (b) the First Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the First Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the First Pre-Funded Warrants held by the holder. Any increase in the First Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\")  and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"), pursuant to a Securities Purchase Agreement with DBV Technologies S.A. (the \"Issuer\") signed on March 27, 2025, purchased in a private placement that is expected to close on or around April 7, 2025 (the \"Offering\"), respectively, 2,299,656 and 25,005,240 units, (\"Pre-Funded Warrant Units\") at price of EUR1.1136 (of which EUR1.1036 will have been pre-funded on the issue date) per Pre-Funded Warrant Unit, each consisting of (i) a pre-funded warrant to purchase an Ordinary Share of the Issuer with an exercise price of EUR0.01 with an expiration date of April 7, 2035 (\"First Pre-Funded Warrant\") (continued in Note 2)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from Note 1) and (ii) a warrant (a \"BS Warrant\") to subscribe for one pre-funded warrant at an exercise price of EUR0.9008 (each, a \"Second Pre-Funded Warrant\") that once acquired allows the holder to subscribe initially for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR0.0175 per Second Pre-Funded Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":2299656,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2299656},"source":{"system":"sec-edgar","filing":"0000950170-25-047967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025047967/ownership.xml","form_type":"4"}},{"id":1289140,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-31T21:59:10.000Z","date":"2025-01-30","kind":"sale","planned":false,"acquired":false,"shares":600,"price":0.85,"value":510.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0419 to EURO 1.00 as of January 30, 2025."}],"balance_after":110510,"source":{"system":"sec-edgar","filing":"0001415889-25-002509","document":"form4-01312025_090106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588925002509/form4-01312025_090106.xml","form_type":"4"}},{"id":1341387,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42317,"kind":"person","name":"Tasse Daniel","position":1,"cik":"0001502785","reported_name":"Tasse Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-05T21:15:08.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":813200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0511 to EURO 1.00 as of December 4, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in four equal annual installments commencing on December 4, 2025, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":813200,"derivative":{"exercise_price":0.89,"expiration_date":"2034-12-04","underlying":"Ordinary Shares","underlying_shares":813200},"source":{"system":"sec-edgar","filing":"0001415889-24-028393","document":"form4-12052024_041202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1502785/000141588924028393/form4-12052024_041202.xml","form_type":"4"}},{"id":1348870,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-11-27T21:15:17.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":565,"price":0.57,"value":322.05,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.048 to EURO 1.00 as of November 25, 2024."}],"balance_after":111110,"source":{"system":"sec-edgar","filing":"0001415889-24-027850","document":"form4-11272024_041114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924027850/form4-11272024_041114.xml","form_type":"4"}},{"id":1348869,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-11-27T21:15:17.000Z","date":"2024-11-22","kind":"sale","planned":false,"acquired":false,"shares":342,"price":0.53,"value":181.26,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0469 to EURO 1.00 as of November 22, 2024."}],"balance_after":111675,"source":{"system":"sec-edgar","filing":"0001415889-24-027850","document":"form4-11272024_041114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924027850/form4-11272024_041114.xml","form_type":"4"}},{"id":1352326,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-11-25T22:13:46.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0546 to EURO 1.00 as of November 21, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":215000,"derivative":{"exercise_price":0.75,"expiration_date":"2034-11-21","underlying":"Ordinary Shares","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001415889-24-027648","document":"form4-11252024_101142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924027648/form4-11252024_101142.xml","form_type":"4"}},{"id":1352325,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-11-25T22:13:46.000Z","date":"2024-11-21","kind":"sale","planned":false,"acquired":false,"shares":2350,"price":0.54,"value":1269.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0546 to EURO 1.00 as of November 21, 2024."}],"balance_after":112017,"source":{"system":"sec-edgar","filing":"0001415889-24-027648","document":"form4-11252024_101142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924027648/form4-11252024_101142.xml","form_type":"4"}},{"id":1352324,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-11-25T22:13:46.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":114367,"source":{"system":"sec-edgar","filing":"0001415889-24-027648","document":"form4-11252024_101142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924027648/form4-11252024_101142.xml","form_type":"4"}},{"id":1352963,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72649,"kind":"person","name":"Boucinha Virginie","position":1,"cik":"0001999496","reported_name":"Boucinha Virginie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-11-25T17:12:40.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":113000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0546 to EURO 1.00 as of November 21, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":113000,"derivative":{"exercise_price":0.75,"expiration_date":"2034-11-21","underlying":"Ordinary Shares","underlying_shares":113000},"source":{"system":"sec-edgar","filing":"0001415889-24-027646","document":"form4-11252024_101137.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999496/000141588924027646/form4-11252024_101137.xml","form_type":"4"}},{"id":1352962,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72649,"kind":"person","name":"Boucinha Virginie","position":1,"cik":"0001999496","reported_name":"Boucinha Virginie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-11-25T17:12:40.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001415889-24-027646","document":"form4-11252024_101137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999496/000141588924027646/form4-11252024_101137.xml","form_type":"4"}},{"id":1445085,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-07-31T21:32:14.000Z","date":"2024-07-29","kind":"sale","planned":false,"acquired":false,"shares":1785,"price":0.98,"value":1749.3,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0823 to EURO 1.00 as of July 29, 2024."}],"balance_after":79367,"source":{"system":"sec-edgar","filing":"0001415889-24-020466","document":"form4-07312024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924020466/form4-07312024_090711.xml","form_type":"4"}},{"id":1498791,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-05-29T20:15:09.000Z","date":"2024-05-24","kind":"sale","planned":false,"acquired":false,"shares":660,"price":1.36,"value":897.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0820 to EURO 1.00 as of May 24, 2024."}],"balance_after":81152,"source":{"system":"sec-edgar","filing":"0001415889-24-014759","document":"form4-05292024_040504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924014759/form4-05292024_040504.xml","form_type":"4"}},{"id":1498790,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-05-29T20:15:09.000Z","date":"2024-05-22","kind":"sale","planned":false,"acquired":false,"shares":382,"price":1.38,"value":527.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0819 to EURO 1.00 as of May 22, 2024."}],"balance_after":81812,"source":{"system":"sec-edgar","filing":"0001415889-24-014759","document":"form4-05292024_040504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000141588924014759/form4-05292024_040504.xml","form_type":"4"}},{"id":1583717,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42317,"kind":"person","name":"Tasse Daniel","position":1,"cik":"0001502785","reported_name":"Tasse Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Ordinary Shares","published_at":"2024-03-11T20:15:38.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":17094,"price":0.83,"value":14188.02,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADS\"), each of which currently represents one-half of one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represent the ADS price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8123 to $0.8612 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":17094,"source":{"system":"sec-edgar","filing":"0001415889-24-007503","document":"form4-03112024_040312.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1502785/000141588924007503/form4-03112024_040312.xml","form_type":"4"}},{"id":1653695,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42909,"kind":"person","name":"Ndu Adora","position":1,"cik":"0001865210","reported_name":"Ndu Adora","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-08T22:02:03.000Z","date":"2024-02-06","kind":"purchase","planned":false,"acquired":true,"shares":1825,"price":0.89,"value":1624.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADS\"), each of which currently represents one-half of one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represent the ADS price."}],"balance_after":1825,"source":{"system":"sec-edgar","filing":"0001415889-24-003031","document":"form4-02082024_100252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865210/000141588924003031/form4-02082024_100252.xml","form_type":"4"}},{"id":1704310,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-12-19T21:44:07.000Z","date":"2023-11-22","kind":"sale","planned":false,"acquired":false,"shares":2245,"price":1.74,"value":3906.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0941 to EURO 1.00 as of November 22, 2023."}],"balance_after":82194,"source":{"system":"sec-edgar","filing":"0001209191-23-059182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123059182/doc4.xml","form_type":"4"}},{"id":1730839,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42317,"kind":"person","name":"Tasse Daniel","position":1,"cik":"0001502785","reported_name":"Tasse Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-22T12:04:17.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":806672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0928 to EURO 1.00 as of November 20, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":806672,"derivative":{"exercise_price":2.19,"expiration_date":"2033-11-20","underlying":"Ordinary Shares","underlying_shares":806672},"source":{"system":"sec-edgar","filing":"0001209191-23-056409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1502785/000120919123056409/doc4.xml","form_type":"4"}},{"id":1730774,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-22T12:03:25.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0928 to EURO 1.00 as of November 20, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":215000,"derivative":{"exercise_price":2.19,"expiration_date":"2033-11-20","underlying":"Ordinary Shares","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001209191-23-056408","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123056408/doc4.xml","form_type":"4"}},{"id":1730773,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-11-22T12:03:25.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":84439,"source":{"system":"sec-edgar","filing":"0001209191-23-056408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123056408/doc4.xml","form_type":"4"}},{"id":1731545,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72649,"kind":"person","name":"Boucinha Virginie","position":1,"cik":"0001999496","reported_name":"Boucinha Virginie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-22T07:05:00.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":113000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0928 to EURO 1.00 as of November 20, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":113000,"derivative":{"exercise_price":2.19,"expiration_date":"2033-11-20","underlying":"Ordinary Shares","underlying_shares":113000},"source":{"system":"sec-edgar","filing":"0001209191-23-056410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999496/000120919123056410/doc4.xml","form_type":"4"}},{"id":1731544,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":72649,"kind":"person","name":"Boucinha Virginie","position":1,"cik":"0001999496","reported_name":"Boucinha Virginie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-11-22T07:05:00.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0001209191-23-056410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999496/000120919123056410/doc4.xml","form_type":"4"}},{"id":1795107,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":38639,"kind":"person","name":"MORRIS TIMOTHY E","position":1,"cik":"0001191286","reported_name":"MORRIS TIMOTHY E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-08-28T16:35:24.000Z","date":"2023-08-25","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":1.52,"value":18240.0,"ownership":{"direct":true},"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-23-047517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191286/000120919123047517/doc4.xml","form_type":"4"}},{"id":1808286,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42317,"kind":"person","name":"Tasse Daniel","position":1,"cik":"0001502785","reported_name":"Tasse Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-14T20:32:50.000Z","date":"2022-11-21","kind":"grant","planned":false,"acquired":true,"shares":764386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0242 to EURO 1.00 as of November 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":764386,"derivative":{"exercise_price":3.07,"expiration_date":"2032-11-21","underlying":"Ordinary Shares","underlying_shares":764386},"source":{"system":"sec-edgar","filing":"0001209191-23-045642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1502785/000120919123045642/doc4.xml","form_type":"4"}},{"id":1808192,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-14T20:32:21.000Z","date":"2022-11-21","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0242 to EURO 1.00 as of November 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the shares subject to the option vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":115000,"derivative":{"exercise_price":3.07,"expiration_date":"2032-11-21","underlying":"Ordinary Shares","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-23-045641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045641/doc4.xml","form_type":"4"}},{"id":1808191,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-14T20:32:21.000Z","date":"2022-07-29","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0226 to EURO 1.00 as of July 29, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on July 29, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":100000,"derivative":{"exercise_price":4.83,"expiration_date":"2032-07-29","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-045641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045641/doc4.xml","form_type":"4"}},{"id":1808190,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-08-14T20:32:21.000Z","date":"2023-05-24","kind":"sale","planned":false,"acquired":false,"shares":469,"price":3.54,"value":1660.26,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares sold to satisfy withholding tax obligations upon the the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0746 to EURO 1.00 as of May 24, 2023."}],"balance_after":49439,"source":{"system":"sec-edgar","filing":"0001209191-23-045641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045641/doc4.xml","form_type":"4"}},{"id":1808189,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-08-14T20:32:21.000Z","date":"2022-11-24","kind":"sale","planned":false,"acquired":false,"shares":1792,"price":2.88,"value":5160.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares sold to satisfy withholding tax obligations upon the the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0409 to EURO 1.00 as of November 24, 2022."}],"balance_after":49908,"source":{"system":"sec-edgar","filing":"0001209191-23-045641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045641/doc4.xml","form_type":"4"}},{"id":1808188,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-08-14T20:32:21.000Z","date":"2022-11-21","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit RSU award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date."}],"balance_after":51700,"source":{"system":"sec-edgar","filing":"0001209191-23-045641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045641/doc4.xml","form_type":"4"}},{"id":1808187,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-08-14T20:32:21.000Z","date":"2022-07-29","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on July 29, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date."}],"balance_after":34200,"source":{"system":"sec-edgar","filing":"0001209191-23-045641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045641/doc4.xml","form_type":"4"}},{"id":1808186,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":110563,"kind":"person","name":"Robitaille Sebastien","position":1,"cik":"0001838818","reported_name":"Robitaille Sebastien","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-14T20:31:39.000Z","date":"2022-11-21","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0242 to EURO 1.00 as of November 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":65000,"derivative":{"exercise_price":3.07,"expiration_date":"2032-11-21","underlying":"Ordinary Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-045640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045640/doc4.xml","form_type":"4"}},{"id":1808185,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":110563,"kind":"person","name":"Robitaille Sebastien","position":1,"cik":"0001838818","reported_name":"Robitaille Sebastien","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-08-14T20:31:39.000Z","date":"2022-11-21","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date."}],"balance_after":36500,"source":{"system":"sec-edgar","filing":"0001209191-23-045640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919123045640/doc4.xml","form_type":"4"}},{"id":1816044,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":79032,"kind":"person","name":"SOLAND DANIEL B","position":1,"cik":"0001318485","reported_name":"SOLAND DANIEL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-08-03T16:40:44.000Z","date":"2023-08-01","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.62,"value":24300.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADS\"), each of which currently represents one-half of one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represent the ADS price."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-23-044458","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1318485/000120919123044458/doc4.xml","form_type":"4"}},{"id":2234684,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":3,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2022-06-13T21:27:43.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":11732979,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Exercisable for 0.10 EUR per warrant on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants (\"Pre-Funded Warrants\"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants (\"Pre-Funded Warrants\"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants (\"Pre-Funded Warrants\"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate."}],"balance_after":11732979,"derivative":{"expiration_date":"2032-06-13","underlying":"Ordinary Shares","underlying_shares":11732979},"source":{"system":"sec-edgar","filing":"0001209191-22-036411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919122036411/doc4.xml","form_type":"4"}},{"id":2234683,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":3,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2022-06-13T21:27:43.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":1383352,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Exercisable for 0.10 EUR per warrant on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants (\"Pre-Funded Warrants\"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants (\"Pre-Funded Warrants\"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and the Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants (\"Pre-Funded Warrants\"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate."}],"balance_after":1383352,"derivative":{"expiration_date":"2032-06-13","underlying":"Ordinary Shares","underlying_shares":1383352},"source":{"system":"sec-edgar","filing":"0001209191-22-036411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919122036411/doc4.xml","form_type":"4"}},{"id":2234682,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":3,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2022-06-13T21:27:43.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":10622568,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the \"Offering\") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the \"Offering\") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate."}],"balance_after":14575984,"source":{"system":"sec-edgar","filing":"0001209191-22-036411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919122036411/doc4.xml","form_type":"4"}},{"id":2234681,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":3,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2022-06-13T21:27:43.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":1252432,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the \"Offering\") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and the Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the \"Offering\") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate."}],"balance_after":1585054,"source":{"system":"sec-edgar","filing":"0001209191-22-036411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919122036411/doc4.xml","form_type":"4"}},{"id":2494836,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42317,"kind":"person","name":"Tasse Daniel","position":1,"cik":"0001502785","reported_name":"Tasse Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-24T21:15:03.000Z","date":"2021-11-22","kind":"grant","acquired":true,"shares":274000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."}],"balance_after":274000,"derivative":{"exercise_price":6.62,"expiration_date":"2031-11-22","underlying":"Ordinary Shares","underlying_shares":274000},"source":{"system":"sec-edgar","filing":"0001209191-21-066789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1502785/000120919121066789/doc4.xml","form_type":"4"}},{"id":2494746,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-24T21:13:41.000Z","date":"2021-11-22","kind":"grant","acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."}],"balance_after":95400,"derivative":{"exercise_price":6.62,"expiration_date":"2031-11-22","underlying":"Ordinary Shares","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001209191-21-066788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919121066788/doc4.xml","form_type":"4"}},{"id":2494745,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":27446,"kind":"person","name":"Mohideen Pharis","position":1,"cik":"0001760395","reported_name":"Mohideen Pharis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-24T21:13:41.000Z","date":"2021-11-22","kind":"grant","acquired":true,"shares":8700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date."}],"balance_after":24200,"source":{"system":"sec-edgar","filing":"0001209191-21-066788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919121066788/doc4.xml","form_type":"4"}},{"id":2494743,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":110563,"kind":"person","name":"Robitaille Sebastien","position":1,"cik":"0001838818","reported_name":"Robitaille Sebastien","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-24T21:12:28.000Z","date":"2021-11-22","kind":"grant","acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."}],"balance_after":51000,"derivative":{"exercise_price":6.62,"expiration_date":"2031-11-22","underlying":"Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001209191-21-066786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919121066786/doc4.xml","form_type":"4"}},{"id":2494742,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":110563,"kind":"person","name":"Robitaille Sebastien","position":1,"cik":"0001838818","reported_name":"Robitaille Sebastien","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-24T21:12:28.000Z","date":"2021-11-22","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the Issuer's ordinary shares underlying a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date."}],"balance_after":28500,"source":{"system":"sec-edgar","filing":"0001209191-21-066786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919121066786/doc4.xml","form_type":"4"}},{"id":2672323,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":42909,"kind":"person","name":"Ndu Adora","position":1,"cik":"0001865210","reported_name":"Ndu Adora","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-06-11T20:56:01.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":6837,"price":7.12,"value":48679.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."}],"balance_after":6837,"derivative":{"exercise_price":13.09,"exercise_date":"2021-06-10","expiration_date":"2025-06-10","underlying":"Ordinary Shares","underlying_shares":6837},"source":{"system":"sec-edgar","filing":"0001209191-21-039889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865210/000120919121039889/doc4.xml","form_type":"4"}},{"id":2671308,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":41602,"kind":"person","name":"Monges Viviane","position":1,"cik":"0001838204","reported_name":"Monges Viviane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-06-11T20:52:37.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":5000,"price":7.12,"value":35600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."}],"balance_after":5000,"derivative":{"exercise_price":13.09,"exercise_date":"2021-06-10","expiration_date":"2025-06-10","underlying":"Ordinary Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-039884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919121039884/doc4.xml","form_type":"4"}},{"id":2671307,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":33772,"kind":"person","name":"Rao Madduri Ravin","position":1,"cik":"0001792006","reported_name":"Rao Madduri Ravin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-06-11T20:48:45.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":6837,"price":7.12,"value":48679.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."}],"balance_after":6837,"derivative":{"exercise_price":13.09,"exercise_date":"2021-06-10","expiration_date":"2025-06-10","underlying":"Ordinary Shares","underlying_shares":6837},"source":{"system":"sec-edgar","filing":"0001209191-21-039881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613780/000120919121039881/doc4.xml","form_type":"4"}},{"id":2671515,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":79032,"kind":"person","name":"SOLAND DANIEL B","position":1,"cik":"0001318485","reported_name":"SOLAND DANIEL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-06-11T16:58:00.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":6837,"price":7.12,"value":48679.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."}],"balance_after":6837,"derivative":{"exercise_price":13.09,"exercise_date":"2021-06-10","expiration_date":"2025-06-10","underlying":"Ordinary Shares","underlying_shares":6837},"source":{"system":"sec-edgar","filing":"0001209191-21-039890","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1318485/000120919121039890/doc4.xml","form_type":"4"}},{"id":2671556,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":38639,"kind":"person","name":"MORRIS TIMOTHY E","position":1,"cik":"0001191286","reported_name":"MORRIS TIMOTHY E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-06-11T16:54:17.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":6837,"price":7.12,"value":48679.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."}],"balance_after":6837,"derivative":{"exercise_price":13.09,"exercise_date":"2021-06-10","expiration_date":"2025-06-10","underlying":"Ordinary Shares","underlying_shares":6837},"source":{"system":"sec-edgar","filing":"0001209191-21-039886","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191286/000120919121039886/doc4.xml","form_type":"4"}},{"id":2671566,"issuer":{"id":5096,"kind":"organization","name":"DBV Technologies S.A."},"owners":[{"id":138355,"kind":"person","name":"DE ROSEN MICHEL","position":1,"cik":"0001187148","reported_name":"DE ROSEN MICHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-06-11T16:50:36.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":6837,"price":7.12,"value":48679.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021."}],"balance_after":6837,"derivative":{"exercise_price":13.09,"exercise_date":"2021-06-10","expiration_date":"2025-06-10","underlying":"Ordinary Shares","underlying_shares":6837},"source":{"system":"sec-edgar","filing":"0001209191-21-039882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187148/000120919121039882/doc4.xml","form_type":"4"}}]}